Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES)

Intensive Statin and Antiplatelet Therapy for High-risk Intracranial or Extracranial Atherosclerosis (INSPIRES)

Large-artery stenosis plays an important role in the occurrence of ischemic stroke. The primary purpose of this study is to evaluate the efficacy and safety of intensive antiplatelet therapy versus standard antiplatelet therapy and immediate high-intensity statin therapy (80mg atorvastatin) versus delayed high-intensity statin therapy (40mg atorvastatin) and intensive antiplatelet combined with immediate high-intensity statin therapy (80mg atorvastatin) versus standard antiplatelet combined with delayed high-intensity statin therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis.

Study Overview

• Status: Active, not recruiting
• Conditions: Transient Ischemic Attack; Acute Stroke
• Intervention / Treatment: Drug: Intensive antiplatelet; Drug: Immediate high-intensity statin; Drug: Delayed high-intensity statin; Drug: Standard antiplatelet

Detailed Description

Large-artery atherosclerotic stenosis is the main cause of ischemic stroke, especially in Asian population. However, targeted treatment evidence for large-artery atherosclerotic stenosis is limited according to the current guidelines. And also, randomized trial for statin therapy in patients with acute large arterial stenosis at early stage is still limited. The primary purpose of this study is to evaluate the efficacy and safety of intensive antiplatelet therapy versus standard antiplatelet therapy in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis; the efficacy and safety of immediate high-intensity statin therapy (80mg atorvastatin) versus delayed high-intensity statin therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis; and the efficacy and safety of intensive antiplatelet combined with immediate high-intensity statin therapy (80mg atorvastatin) versus standard antiplatelet combined with delayed high-intensity statin therapy (40mg atorvastatin) in reducing the risk of stroke at 90 days in patients with acute and high-risk symptomatic extracranial or intracranial arterial stenosis.

This trial is a randomized, double-blind, placebo-controlled, multicenter, 2×2 factorial designed clinical trial. 6100 patients in 250 centers in China will be enrolled with one of the following situations (1) Mild ischemic stroke (NIHSS 4~5) within 24 hours of onset meets any of the following imaging conditions: a) Acute single cerebral infarction with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),b) Acute multiple cerebral infarction (considered to be caused by large artery atherosclerosis, including non-stenotic vulnerable plaque);Or (2) Moderate-to-high-risk TIA (ABCD2≥4) or mild ischemic stroke (NIHSS≤5) within 24 to 72 hours of onset meets any of the following imaging conditions: a) Medium and high risk TIA with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),b) Acute single cerebral infarction with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%),c) Acute multiple cerebral infarction (considered to be caused by large artery atherosclerosis, including non-stenotic vulnerable plaque) . Patients will be randomly assigned into 4 groups according to the ratio of 1:1:1:1:

1. Intensive antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin)
2. Intensive antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin)
3. Standard antiplatelet therapy + immediate high-intensity statin therapy (80mg atorvastatin)
4. Standard antiplatelet therapy + delayed high-intensity statin therapy (40mg atorvastatin)

Face to face interviews will be made at baseline, 7, 14 (or hospital discharge), 90 ± 7 days and 12th month ± 14 days after randomization.

Survival curves will be estimated for the primary outcome using the Kaplan-Meier procedure and compared using a Cox regression model Wald test, stratified by the opposite arm of the factorial design. Safety outcomes will be calculated using the Kaplan-Meier curve to simulate the 3-month cumulative risk, and the Cox proportional hazards model to calculate the HR and 95% confidence interval.

Primary outcome is defined as stroke (including hemorrhagic and ischemic stroke). Secondary outcomes include composite vascular events (stroke, myocardial infarction, and cardiovascular death); ischemic stroke; transient ischemic attack; myocardial infarction; vascular death; all-cause death; poor functional outcome (mRS 2-6); and quality of life (EQ-5D scale). Safety outcomes, relating to antiplatelet therapy (i.e. bleeding, intracranial hemorrhage, and adverse events) and statin therapy (i.e. hepatotoxicity, muscle toxicity and adverse events) will be investigated.

• Study Type: Interventional
• Enrollment (Actual): 6100
• Phase: Phase 3

Contacts and Locations

Study Locations

• China
  • Anshan, China
    • Anshan Central Hospital
  • Anshan, China
    • General Hospital of Anshan Iron and Steel Company
  • Anyang, China
    • Anyang People's Hospital
  • Baoding, China
    • Baoding First Central Hospital
  • Beijing, China
    • Beijing Hepingli Hospital
  • Benxi, China
    • Benxi Central Hospital
  • Changsha, China
    • First Hospital of Changsha
  • Changsha, China
    • Second people's Hospital of Hunan Province
  • Changsha, China
    • Xiangya Third Hospital of Central South University
  • Changzhi, China
    • Changzhi Medical College Affiliated Heping Hospital
  • Changzhi, China
    • Changzhi People's Hospital
  • Changzhi, China
    • Lu'an Group General Hospital
  • Changzhou, China
    • Changzhou Second People's Hospital
  • Changzhou, China
    • Changzhou Wujin Hospital of Traditional Chinese Medicine
  • Chongqing, China
    • Chongqing Sanxia Central Hospital
  • Chongqing, China
    • Southwest Hospital affiliated to the Army Military Medical University
  • Dali, China
    • People's Hospital of Dali Bai Autonomous Prefecture
  • Dalian, China
    • Dalian Central Hospital
  • Dalian, China
    • Dalian Friendship Hospital
  • Dalian, China
    • Second people's Hospital of Dalian
  • Dalian, China
    • Xinhua Hospital Affiliated to Dalian University
  • Datong, China
    • Datong Third People's Hospital
  • Dazhou, China
    • Dazhou Central Hospital
  • Dongguan, China
    • Dongguan Hong Wah hospital
  • Dongguan, China
    • Donghua Hospital
  • Dongyang, China
    • Dongyang People's Hospital
  • Dongying, China
    • People's Hospital of Dongying District
  • Fushun, China
    • General Hospital of Fushun Mining Bureau
  • Fuxin, China
    • Fuxin Mining Group General Hospital
  • Guilin, China
    • Nanxi Mountain hospital in Guangxi District
  • Guiyang, China
    • Guiyang Second Hospital
  • Ha'erbin, China
    • General Hospital of the General Administration of agriculture and reclamation of Heilongjiang
  • Handan, China
    • Handan Central Hospital
  • Handan, China
    • Handan First Hospital
  • Hebei, China
    • Second Hospital of Hebei Medical University
  • Hengshui, China
    • Hengshui Sixth People's Hospital
  • Hengyang, China
    • Nanhua Hospital Affiliated to Nanhua University
  • Hohhot, China
    • The Inner Mongolia Autonomous Region people's Hospital
  • Jiamusi, China
    • First Affiliated Hospital of Jiamusi University
  • Jiamusi, China
    • Jiamusi Central Hospital
  • Jilin, China
    • Jilin Electric Power Hospital
  • Jilin, China
    • Jinlin Central Hospital
  • Jilin, China
    • Jinlin People's Hospital
  • Jilin, China
    • Second Hospital of Jilin University
  • Jinan, China
    • Qianfo Hill Hospital of Shandong Province
  • Jinan, China
    • Shandong Transportation Hospital
  • Jiujiang, China
    • Affiliated Hospital of Jiujiang University
  • Jixi, China
    • Jixi People's Hospital
  • Kai Feng, China
    • Kaifeng Central Hospital
  • Liaocheng, China
    • Liaocheng Brain Hospital
  • Liaocheng, China
    • Liaocheng Second People's Hospital
  • Liaoyang, China
    • Liaoyang Central Hospital
  • Linfen, China
    • Linfen People's Hospital
  • Luoyang, China
    • Second Affiliated Hospital of Henan University of Science and Technology
  • Luzhou, China
    • Luzhou Hospital of traditional Chinese Medicine
  • Mishan, China
    • Mishan People's Hospital
  • Mudanjiang, China
    • Mudanjiang Second People's Hospital
  • Nanchang, China
    • Fourth Affiliated Hospital of Nanchang University
  • Nanchang, China
    • Third Affiliated Hospital of Nanchang University
  • Nanjing, China
    • Wuxi Affiliated Hospital of Nanjing University of Chinese Medicine
  • Ningbo, China
    • Li Huili Hospital of Ningbo Medical Center
  • Ningbo, China
    • Ningbo second hospital
  • Ningde, China
    • Ningde People's Hospital
  • Panjin, China
    • Panjin Central Hospital
  • Pingdingshan, China
    • Pindingshan First People's Hospital
  • Qiqihar, China
    • Qiqihar first hospital
  • Rizhao, China
    • Ruzhou First People's Hospital
  • Sanmenxia, China
    • Sanmenxia Central Hospital
  • Shanghai, China
    • Fifth People's Hospital of Shanghai City, affiliated to Fudan University
  • Shanghai, China
    • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
  • Shanxi, China
    • Second Hospital of Shanxi Medical University
  • Shaoxing, China
    • Shengzhou People's Hospital
  • Shenyang, China
    • Heilongjiang Agriculture and Reclamation Bei'an Administration Central Hospital
  • Shenzhen, China
    • Shenzhen Second People's Hospital
  • Shijiazhuang, China
    • Shijiazhuang Pingan Hospital
  • Suzhou, China
    • First Hospital Affiliated to Suzhou University
  • Suzhou, China
    • The Second Hospital Affiliated to Suzhou University
  • Taizhou, China
    • Taizhou First People's Hospital
  • Tangshan, China
    • Affiliated Hospital of North China Polytechnic University
  • Tangshan, China
    • Tangshan Workers' Hospital
  • Tianjin, China
    • Tianjin Fourth Central Hospital
  • Tieling, China
    • Tieling Central Hospital
  • Weifang, China
    • Gaomi People's Hospital
  • Weihai, China
    • People's Hospital of Wendeng District
  • Wuhan, China
    • People's Hospital of Wuhan University
  • Wuhan, China
    • Wuhan Central Hospital
  • Wuwei, China
    • Gansu Academy of Medical Sciences, Wuwei
  • Wuxi, China
    • Wuxi People's Hospital
  • Wuxi, China
    • Wuxi Second People's Hospital
  • Xi'an, China
    • Xi'an 141 hospital
  • Xi'an, China
    • Xian First Hospital
  • Xinxiang, China
    • Xinxiang Central Hospital
  • Xinyang, China
    • Xinyang Central Hospital
  • Xuchang, China
    • Xuchang Central Hospital
  • Xuzhou, China
    • General Hospital of Xuzhou Mining Group
  • Xuzhou, China
    • Xuzhou First People's Hospital
  • Yantai, China
    • Yantai Yuhuangding Hospital Affiliated to Qiingdao University
  • Yibin, China
    • Yibin First People's Hospital
  • Yichang, China
    • Yichang First People's Hospital
  • Yingkou, China
    • Yingkou Central Hospital
  • Yueyang, China
    • Yueyang Hospital of Integrated Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine
  • Yunnan, China
    • Dehong People's Hospital of Yunnan
  • Zaozhuang, China
    • Zaozhuang Mining Group Zaozhuang hospital
  • Zhangjiagang, China
    • Zhangjiagang First People's Hospital
  • Zhangjiagang, China
    • Zhangjiagang Traditional Chinese Medicine Hospital
  • Zhangjiakou, China
    • Workers' Hospital of Hebei iron and Steel Group Xuanhua iron and Steel Co., Ltd.
  • Zhengzhou, China
    • Central Hospital of the Yellow River
  • Zhengzhou, China
    • Zhengzhou First People's Hospital
  • Zhenjiang, China
    • Affiliated Hospital of Jiangsu University
  • Zhoukou, China
    • Zhoukou Yongshan hospital
  • Zhumadian, China
    • Zhumadian Central Hospital
  • Zigong, China
    • Zigong First People's Hospital
  • Beijing
    • Beijing, Beijing, China, 100050
      • Tiantan Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age :35-80 years old , male or female;
2. Any of the following three two situations:

(1) Mild ischemic stroke (NIHSS 4 to 5 points) within 24 hours of onset meets any of the following imaging conditions:

1. Acute single cerebral infarction with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%)
2. Acute multiple cerebral infarction (considered to be caused by large artery atherosclerosis, including non-stenotic vulnerable plaque)

Or (2) Moderate-to-high-risk TIA (ABCD2≥4 points) or mild ischemic stroke (NIHSS≤5 points) within 24 to 72 hours of onset meets any of the following imaging conditions:

1. Medium and high risk TIA with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%)
2. Acute single cerebral infarction with criminal intracranial and extracranial atherosclerotic stenosis (stenosis rate ≥50%)
3. Acute multiple cerebral infarction (considered to be caused by large artery atherosclerosis, including non-stenotic vulnerable plaque)

The rate of intracranial artery stenosis is assessed by MRA, CTA, or DSA according to WASID standards; the rate of extracranial artery stenosis is assessed by carotid ultrasound, CEMRA, CTA or DSA, according to NASCET standards; 3. Signed informed consent

Exclusion Criteria:

1. Specific cardiogenic ischemic cerebrovascular diseases(eg. combined with atrial fibrillation, heart valve prosthesis, atrial myxoma, endocarditis, etc.)
2. Other ischemic cerebrovascular diseases with specific causes (eg. aortic dissection, vasculitis, vascular malformation, etc.)
3. Non-cerebral vascular disease (eg. intracranial tumors, multiple sclerosis)
4. Cerebral infarction of large area (infarct size greater than half the single lobe area)
5. CT indicating hemorrhagic transformation of cerebral infarction before randomization

6. Patients with pre-existing contraindications of using clopidogrel, aspirin or statin drugs:

   Known history of allergy ; Severe heart failure and asthma ; Coagulant disorders and systemic bleeding ; Pre-existing drug - induced blood system disease or abnormal liver function ; Leukopenia (< 2×109/l) or thrombocytopenia (<100×109/l) ; active liver disease ; pregnancy or lactation period ; Severe heart failure：New York Heart Association (NYHA) Functional Classification III and IV

7. MRS > 2 before the onset
8. Use of intravenous or arterial thrombolysis intravascular therapy or bridge therapy after onset
9. Use of defibrinating therapy like snake venom, defibrase, lumbrokinase, etc. or use of anticoagulant therapy like argatroban, or use of antiplatelet therapy except clopidogrel and aspirin, such as tirofiban, ticagrelor, ozagrel, and so on after onset.
10. Creatine Kinase(CK) more than 5 times of the upper limit of normal value after onset
11. Use of drugs affecting the metabolism of statins such as immune-suppressive drugs, antifungal agents, or fibrates drugs and so on, within 14 days before randomization.
12. Severe hepatic or renal insufficiency (Note: Severe hepatic insufficiency refers to the ALT value > 2 times the upper limit of normal value or AST times > 2 times the upper limit of normal value; Severe hepatic insufficiency is refers to creatinine values > 1.5 times he upper limit of normal value or GFR < 40 ml/min/1.73 m2)
13. Usage of dual antiplatelet therapy with aspirin plus clopidogrel within 14 days before randomization. (patients who received dual antiplatelet therapy (aspirin combined with clopidogrel) but did not use clopidogrel with loading dose after onset were excluded)
14. Use of Intensive statin therapy within 14 days before randomization（atorvastatin ≥40mg/d or rosuvastatin ≥ 20mg/d）.
15. Pre-existing intracranial hemorrhage（eg. ICH, SAH）
16. Gastrointestinal bleeding or major surgery occurred within 90 days before randomization.
17. Pre-existing extracranial angioplasty or vascular surgery
18. Anticipated requirement for long-term non-study antiplatelet drugs, or non-steroid anti-inflammatory drugs.
19. Experimental drugs need to stop due to angioplasty or vascular surgery, which was planned or likely to perform within 90 days after randomization
20. Patients with severe disease expected to live for less than 90 days
21. Pregnant or childbearing-age women who have no effective contraceptives or positive pregnancy test records
22. Patients who are undergoing experimental drugs or device tests
23. Unable to finish the follow-up of 90 days due to geographical factor or other reasons（eg. dementia, alcoholism, substance abuse, severe mental disease, etc.）

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: DAPT + immediate high-intensity statin; This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.	Drug: Intensive antiplatelet; Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day Day22 - 90: clopidogrel 75mg/day+aspirin placebo; Other Names: Dual antiplatelet; Drug: Immediate high-intensity statin; Day 1 - 21：Atorvastatin calcium 80mg/day Day 22 - 90：Atorvastatin calcium 40mg/day; Other Names: Immediate Atorvastatin
Other: DAPT + delayed high-intensity statin; This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.	Drug: Intensive antiplatelet; Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day Day22 - 90: clopidogrel 75mg/day+aspirin placebo; Other Names: Dual antiplatelet; Drug: Delayed high-intensity statin; Day 1 - 3：Atorvastatin calcium placebo Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo Day 22 - 90：Atorvastatin calcium 40mg/day; Other Names: Delayed Atorvastatin
Other: Aspirin+immediate high-intensity statin; This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.	Drug: Immediate high-intensity statin; Day 1 - 21：Atorvastatin calcium 80mg/day Day 22 - 90：Atorvastatin calcium 40mg/day; Other Names: Immediate Atorvastatin; Drug: Standard antiplatelet; Day 1: Aspirin 100-300mg/day + clopidogrel placebo Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo; Other Names: Aspirin
Placebo Comparator: Aspirin+delayed high-intensity statin; This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.	Drug: Delayed high-intensity statin; Day 1 - 3：Atorvastatin calcium placebo Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo Day 22 - 90：Atorvastatin calcium 40mg/day; Other Names: Delayed Atorvastatin; Drug: Standard antiplatelet; Day 1: Aspirin 100-300mg/day + clopidogrel placebo Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo; Other Names: Aspirin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Stroke	Symptoms and signs of acute neurological deficits caused by sudden focal or whole brain, spinal cord or retinal vascular damage, which are related to cerebral circulatory disorders, including hemorrhagic and ischemic stroke	90 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Composite vascular events	stroke (including hemorrhagic and ischemic stroke), myocardial infarction, and cardiovascular death.	90 days
Ischemic stroke	An acute focal infarction of the brain or retina. Criteria:(1) acute onset of a new focal neurological deficit with clinical or imaging evidence of infarction lasting more than 24 hours and not attributable to a non-ischemic etiology (not associated with brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease); or (2) acute onset of a new focal neurological deficit and not attributable to a non-ischemic etiology lasting less than 24 hours, but accompanied by neuroimaging evidence of new brain infarction; or, (3) rapid worsening of an existing focal neurological deficit (an increase in NIHSS of ≥4 on the basis of a primary ischemic stroke, excluding hemorrhagic transformation or symptomatic cranial disease after infarction) lasting more than 24 hours and not attributable to a non-ischemic etiology, and accompanied by new ischemic changes on brain MRI or CT.	90 days
Transient ischemic attack	A neurological deficit of sudden onset, resolving completely, attributed to focal brain or retinal ischemia without evidence of associated acute focal infarction of the brain. Criteria: rapid onset of a focal neurological deficit that is without evidence of acute focal infarction of the brain, and is not attributable to a non-ischemic etiology (brain infection, trauma, tumor, seizure, severe metabolic disease, or degenerative neurological disease)	90 days
Myocardial infarction	Acute myocardial infarction is diagnosed by the third edition of the international general diagnostic criteria (Glob Heart. 2012 Dec;7(4):275-95)	90 days
Vascular death	Vascular death includes stroke, sudden cardiac death, acute myocardial infarction, heart failure, pulmonary embolism, heart / cerebrovascular intervention or surgery (death unrelated to acute MI) and other cardiovascular causes of death [such as: Arrhythmia irrelevant with sudden cardiac death, aortic aneurysm rupture, or peripheral artery disease. Any death of unknown/unclear cause that occurs within 30 days after stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery will be regarded as death due to stroke, myocardial infarction, or cardio-cerebrovascular operation/surgery, respectively.	90 days
All-cause death	All-cause death	90 days
Poor functional outcome	The modified Rankin Scale (mRS)= 2-6	90 days
Quality of life (EQ-5D scale)	EQ-5D scale index score ≤0.5	90 days
Change of atherosclerotic plaque using high-resolution magnetic resonance imaging (HR-MRI)	Change of atherosclerotic plaque using high-resolution magnetic resonance 。 Patients in HR-MRI subgroup only	90 days
Early Neurological Deficits	NIHSS score increase of no less than 2points	7 days
Ordinal stroke or TIA	The new stroke or TIA is classified on a six-level ordered category scale combined vascular events with mRS score at 90 days or at 1year, respectively: fatal stroke (stroke with subsequent death), severe stroke (stroke followed by mRS of 4-5), moderate stroke (stroke followed by mRS of 2-3), mild stroke (stroke followed by mRS of 0-1), TIA and no stroke/TIA.	90 days

Collaborators and Investigators

• Sponsor: Beijing Tiantan Hospital
• Collaborators: Ministry of Science and Technology of the People's Republic of China
• Investigators: Principal Investigator: Yilong Wang, MD, PhD, Beijing Tiantan Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 17, 2018
• Primary Completion (Actual): January 15, 2023
• Study Completion (Estimated): October 30, 2023

Study Registration Dates

• First Submitted: August 15, 2018
• First Submitted That Met QC Criteria: August 15, 2018
• First Posted (Actual): August 17, 2018

Study Record Updates

• Last Update Posted (Actual): July 18, 2023
• Last Update Submitted That Met QC Criteria: July 15, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Keywords: Randomized Controlled Trial; Clinical Trial; Antiplatelet Therapy; Acute Stroke; Multicenter Study; Transient Ischemic Attack; Double Blind Study; Symptomatic Extracranial or Intracranial Arterial Stenosis; Statin Therapy
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Brain Ischemia; Stroke; Ischemic Attack, Transient; Atherosclerosis; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antimetabolites; Anticholesteremic Agents; Hypolipidemic Agents; Lipid Regulating Agents; Atorvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Other Study ID Numbers: 2017YFC1307905

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No